The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
R Perez-Soler - Clinical cancer research, 2004 - AACR
Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 …
receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 …
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non–small-cell lung cancer
R Pérez-Soler - Clinical lung cancer, 2004 - Elsevier
Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
Erlotinib: a new therapeutic approach for non-small cell lung cancer
P Bonomi - Expert opinion on investigational drugs, 2003 - Taylor & Francis
Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …
Erlotinib in non-small cell lung cancer treatment: current status and future development
C Gridelli, MA Bareschino, C Schettino, A Rossi… - The …, 2007 - academic.oup.com
Learning Objectives After completing this course, the reader will be able to: Describe the
molecular mechanism of action of erlotinib. Define clinical and molecular predictors of …
molecular mechanism of action of erlotinib. Define clinical and molecular predictors of …
Select clinical trials of erlotinib (OSI-774) in non–small-cell lung cancer with emphasis on phase III outcomes
LMB Fuster, AB Sandler - Clinical lung cancer, 2004 - Elsevier
Lung cancer is primarily diagnosed during the advanced stage of disease, at which stage
treatment options are severely limited. It is primarily for this reason that lung cancer carries a …
treatment options are severely limited. It is primarily for this reason that lung cancer carries a …
The Current Situation: Erlotinib (Tarceva®) and Gefitinib (Iressa®) in Non-Small Cell Lung Cancer
RL Comis - The oncologist, 2005 - academic.oup.com
Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …
Erlotinib hydrochloride.
J Dowell, JD Minna, P Kirkpatrick - Nature Reviews Drug Discovery, 2005 - nature.com
Abstract Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
B Piperdi, R Perez-Soler - Drugs, 2012 - Springer
Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments
C Gridelli, P Maione, MA Bareschino… - Anticancer …, 2010 - ar.iiarjournals.org
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …